Comparison / Level A vs Level A

Dulaglutide vs Liraglutide

Research Verdict

Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.

Quick Answers

Which is better, Dulaglutide or Liraglutide?

Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.

What is the key difference between Dulaglutide and Liraglutide?

Once-weekly dulaglutide vs. once-daily liraglutide represents a 7-fold reduction in injection frequency with similar CV outcomes - a meaningful adherence advantage for dulaglutide.

Evidence Comparison

Dulaglutide: REWIND HR 0.88 for MACE, once-weekly. Liraglutide: LEADER HR 0.87 for MACE, once-daily. Both FDA approved for T2DM and CV risk reduction. Evidence quality is comparable; dosing frequency is the practical differentiator.

Evidence Context Favoring Dulaglutide

T2DM where reduced injection frequency improves adherence and the REWIND primary prevention population is relevant.

Evidence Context Favoring Liraglutide

T2DM where daily dose titration flexibility is needed, or weight management (liraglutide 3.0 mg/Saxenda has the obesity indication).

Side-by-Side Snapshot

Evidence gradeDulaglutide: Level A
Liraglutide: Level A
Research statusDulaglutide: FDA Approved
Liraglutide: FDA Approved
Primary categoryDulaglutide: Weight Loss & Metabolic
Liraglutide: Weight Loss & Metabolic
Cited studiesDulaglutide: 3
Liraglutide: 2

Read Next